GlassScriptPhysician profile
Rex Campbell Garland
NPI 1902241813
$1,566.87
in general payments reported to CMS, 2019-2025
14 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $70.31 · 2021: $153 · 2022: $128 · 2023: $508 · 2024: $403 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.03 |
| Education | $197.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $572.44 | 2020-2025 | Tecvayli, Darzalex, Carvykti |
| Astellas Pharma US INC | $199.32 | 2023-2024 | Xospata |
| Incyte Corporation | $127.90 | 2023 | Jakafi |
| Glaxosmithkline, LLC. | $127.77 | 2022 | |
| Apellis Pharmaceuticals, INC. | $119.27 | 2024 | Empaveli |
| Janssen Scientific Affairs, LLC | $118.63 | 2023-2024 | Talvey, Tecvayli, Carvykti |
| Celgene Corporation | $114.32 | 2019 | |
| Pfizer INC. | $97.04 | 2024 | |
| Recordati_rare_diseases_inc. | $90.18 | 2025 | Enjaymo |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Garland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.